secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001680367-23-000060
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck reports Q3 net loss $27.5M; SL-172154 PROC ORR ~27% vs 4% benchmark
----------------------------------------------------------------------------

- Net loss of $27.5M ($0.65/share) for Q3 2023 vs $24.6M ($0.58/share) a year ago.
- Cash and investments $101.1M as of Sep 30, 2023, sufficient to fund operations through 2024.
- SL-172154 + PLD in PROC: 3 partial responses out of 11 evaluable patients (27% ORR), acceptable safety.
- Topline data from Phase 1A/B in R/R AML/HR-MDS to be presented at ASH Dec 2023; abstract shows monotherapy response.
- Expect to complete enrollment in PROC expansion and frontline HR-MDS cohorts in Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000168036723000060/0001680367-23-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000168036723000060/sttk-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001680367-23-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer